Published in Hepatology on May 01, 2006
Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06
Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat (2008) 1.85
New antiviral therapies for chronic hepatitis C. Hepatol Int (2010) 1.71
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int (2010) 1.48
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One (2011) 1.39
Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol (2008) 1.39
Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol (2009) 1.22
Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol (2007) 1.22
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol (2011) 1.10
Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver (2012) 1.08
Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol (2009) 0.99
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol (2010) 0.98
APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96
Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. J Infect Dis (2009) 0.95
Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors. Med Microbiol Immunol (2014) 0.95
Chronic hepatitis C. Gut Liver (2011) 0.94
Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population. World J Gastroenterol (2008) 0.93
Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol (2009) 0.92
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol (2012) 0.91
Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J Clin Microbiol (2008) 0.90
Recent trends in the treatment of chronic hepatitis C. Korean J Hepatol (2012) 0.90
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine (2014) 0.89
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med (2014) 0.89
Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat (2009) 0.88
Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol (2007) 0.88
Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol (2012) 0.88
Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. PLoS One (2012) 0.86
Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials (2012) 0.86
Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol (2015) 0.86
Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population. BMC Gastroenterol (2013) 0.84
Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol (2014) 0.84
Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence (2013) 0.83
Tailoring antiviral therapy in hepatitis C. Hepatology (2006) 0.83
Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin. PLoS One (2013) 0.82
Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C. World J Gastroenterol (2013) 0.81
SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol (2012) 0.80
Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success. Can J Gastroenterol (2010) 0.80
Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes. PLoS One (2015) 0.80
Efficacy of 24-week pegylated interferon alpha and ribavirin combination therapy in highly selected patients infected with hepatitis C virus genotype 1. Hepat Mon (2015) 0.79
The role of consensus interferon in the current treatment of chronic hepatitis C viral infection. Gastroenterol Hepatol (N Y) (2008) 0.79
Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat (2010) 0.79
Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin. J Gastroenterol (2011) 0.79
Optimizing the dose and duration of therapy for chronic hepatitis C. Gut Liver (2009) 0.78
Response-guided therapy for HCV. Gastroenterol Hepatol (N Y) (2011) 0.78
Consensus interferon: tailored therapy and the impact of adherence. Dig Dis Sci (2011) 0.78
Treatment of chronic hepatitis C in a slow responder: a case for extended therapy. Nat Rev Gastroenterol Hepatol (2009) 0.78
Big changes are coming in hepatitis C. Curr Gastroenterol Rep (2011) 0.78
Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients. Therap Adv Gastroenterol (2009) 0.77
Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C. World J Hepatol (2010) 0.77
Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b. Int J Clin Exp Med (2015) 0.77
Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. J Gastroenterol (2009) 0.76
HBV and HCV therapy. Viruses (2009) 0.76
Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C. World J Gastroenterol (2010) 0.76
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. PLoS One (2015) 0.76
Treatment options for HCV nonresponders and relapse patients. Gastroenterol Hepatol (N Y) (2010) 0.76
Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1. J Gastroenterol (2013) 0.76
Individualizing HCV Treatment with Peginterferon and Ribavirin: What needs to be Done? Therap Adv Gastroenterol (2009) 0.75
Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals. Biomed Rep (2016) 0.75
Direct-acting antiviral agents in patients with hepatitis C cirrhosis. Gastroenterol Hepatol (N Y) (2012) 0.75
Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin. Pharmgenomics Pers Med (2010) 0.75
Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World J Hepatol (2015) 0.75
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. J Korean Med Sci (2016) 0.75
Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. World J Gastroenterol (2016) 0.75
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6. Hepatology (2007) 0.75
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat (2011) 0.75
Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population. Virol J (2013) 0.75
[New strategies for a better use of peginterferon and ribavirin and new drugs with specifically-targeted antiviral therapy for chronic hepatitis C]. Acta Gastroenterol Latinoam (2007) 0.75
Challenging clinical cases in HCV infection. BMC Infect Dis (2014) 0.75
Spontaneous weight change during chronic hepatitis C treatment: association with virologic response rates. Int J Med Sci (2013) 0.75
Performance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or Serum. J Clin Microbiol (2016) 0.75
Syphilis negatively influences the response to hepatitis C virus treatment in an HIV-infected patient. Top Antivir Med (2012) 0.75
HCV Council - critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int (2015) 0.75
Management of hepatitis c genotype 4 in the liver transplant setting. Saudi J Gastroenterol (2016) 0.75
Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Ther Clin Risk Manag (2017) 0.75
On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula. World J Gastroenterol (2010) 0.75
Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection. Gastroenterology Res (2013) 0.75
Effect of season and sunlight on viral kinetics during hepatitis C virus therapy. BMJ Open Gastroenterol (2017) 0.75
Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C. Dig Dis Sci (2011) 0.75
Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C. Dig Dis Sci (2017) 0.75
Estimates of HCV-1 patients attaining RVR following dual therapy with peg-interferon and ribavirin. Dig Dis Sci (2012) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology (2005) 5.93
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Alcoholic hepatitis. N Engl J Med (2009) 4.98
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol (2004) 3.80
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology (2007) 3.61
Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol (2006) 3.57
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol (2005) 3.27
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology (2006) 3.19
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology (2009) 3.02
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology (2009) 2.97
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology (2007) 2.78
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology (2013) 2.60
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (2014) 2.56
Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol (2007) 2.55
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology (2003) 2.54
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology (2010) 2.48
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol (2004) 2.47
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology (2004) 2.44
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol (2010) 2.43
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol (2010) 2.35
Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol (2002) 2.30
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut (2010) 2.25
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology (2006) 2.21
World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol (2014) 2.17
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology (2008) 2.11
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol (2013) 2.04
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
[Time to think in new ways? Frequent suicide risk assessments can increase the danger of suicide]. Lakartidningen (2010) 2.01
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol (2011) 1.97
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology (2006) 1.97
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology (2008) 1.95